Compare · GLP-1 agonist
Amycretin vs Liraglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Amycretin | Liraglutide | |
|---|---|---|
| Evidence | Preliminary human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere. | A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes. |
| Full profile → | Full profile → |
Amycretin
Amycretin is an investigational drug from Novo Nordisk that has generated some striking early-phase weight-loss numbers, which is exactly why it shows up on peptide forums and gray-market menus. It is a single-molecule ("unimolecular") peptide that activates two receptors at once — the GLP-1…
Liraglutide
Liraglutide is one of the better-studied metabolic drugs of the last fifteen years, and the direct predecessor to semaglutide. Its two approved uses rest on large, replicated, double-blind randomized trials with hard endpoints, so the honest job here is to separate what the evidence firmly supports…